AMEX:LABD   Direxion Daily S&P Biotech Bear 3X Shares
Since LABU Long cut short this week from the previous analysis (ran up 15% and stopped at 3% profit). Entering LABD Long as the next big idea for 5:1 R:R.

Fundamentally, I felt this was the right trade long before once the pharmy companies come out with official vaccines that will leave the majority of the industry in despair as only a select few in the industry will continue to benefit from the Covid story.

相关观点

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。